ArticleBritish journal of cancer2007
Epigenetics provides a new generation of oncogenes and tumour-suppressor genes.
Article in British journal of cancer, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- The Key Role of Mitochondria in Somatic Stem Cell Differentiation: From Mitochondrial Asymmetric Apportioning to Cell Fate.International journal of molecular sciences · 2023Review
- Promoter CpG island hypermethylation and down regulation of XRCC1 gene can augment in the gastric carcinogenesis events.Molecular biology reports · 2021Article
- MicroRNA-129-5p inhibits human glioma cell proliferation and induces cell cycle arrest by directly targeting DNMT3A.American journal of translational research · 2018Article
- Detection and monitoring of hypermethylated RASSF1A in serum from patients with metastatic breast cancer.Clinical epigenetics · 2016Article
- Pathological bases for a robust application of cancer molecular classification.International journal of molecular sciences · 2015Review
- Prolonged re-expression of the hypermethylated gene EPB41L3 using artificial transcription factors and epigenetic drugs.Epigenetics · 2015Article
- The de novo DNA methyltransferase DNMT3A in development and cancer.Epigenetics · 2014Review
- Tumor cell plasticity: the challenge to catch a moving target.Journal of gastroenterology · 2014Review
- DNA methylation alterations in grade II- and anaplastic pleomorphic xanthoastrocytoma.BMC cancer · 2014Article
- Vitamin D and the epigenome.Frontiers in physiology · 2014Review
- DNA methylation and histone modifications of Wnt genes by genistein during colon cancer development.Carcinogenesis · 2013Article
- An Algorithm for Generating Small RNAs Capable of Epigenetically Modulating Transcriptional Gene Silencing and Activation in Human Cells.Molecular therapy. Nucleic acids · 2013Article
- Article
- DUSP16 is an epigenetically regulated determinant of JNK signalling in Burkitt's lymphoma.British journal of cancer · 2010Article
- Article
- Histone Arg modifications and p53 regulate the expression of OKL38, a mediator of apoptosis.The Journal of biological chemistry · 2008Article
- Decitabine-induced demethylation of 5' CpG island in GADD45A leads to apoptosis in osteosarcoma cells.Neoplasia (New York, N.Y.) · 2008Article
- DNA methyltransferase 3B promoter polymorphism and its susceptibility to primary hepatocellular carcinoma in the Chinese Han nationality population: a case-control study.World journal of gastroenterology · 2007Article
Corrections and comments
- Reprint of
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is nowadays recognised as a genetic and epigenetic disease. Much effort has been devoted in the last 30 years to the elucidation of the 'classical' oncogenes and tumour-suppressor genes involved in malignant cell transformation. However, since the acceptance that major disruption of DNA methylation, histone modification and chromatin compartments are a common hallmark of human cancer, epigenetics has come to the fore in cancer research. One piece is still missing from the story: are the epigenetic genes themselves driving forces on the road to tumorigenesis? We are in the early stages of finding the answer, and the data are beginning to appear: knockout mice defective in DNA methyltransferases, methyl-CpG-binding proteins and histone methyltransferases strongly affect the risk of cancer onset; somatic mutations, homozygous deletions and methylation-associated silencing of histone acetyltransferases, histone methyltransferases and chromatin remodelling factors are being found in human tumours; and the first cancer-prone families arising from germline mutations in epigenetic genes, such as hSNF5/INI1, have been described. Even more importantly, all these 'new' oncogenes and tumour-suppressor genes provide novel molecular targets for designed therapies, and the first DNA-demethylating agents and inhibitors of histone deacetylases are reaching the bedside of patients with haematological malignancies.
Identifiers
17393582What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.